DS
AIMT

David Shaw’s Aimmune Therapeutics AIMT Stock Holding History

David Shaw’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-15,530
Closed -$535K – 4314
2020
Q3 		$535K Sell
15,530
-141,818
-90% -$3.02M ﹤0.01% 3198
2020
Q2 		$2.63M Buy
157,348
+145,148
+1,190% +$2.46M ﹤0.01% 2180
2020
Q1 		$176K Sell
12,200
-19,115
-61% -$489K ﹤0.01% 3684
2019
Q4 		$1.05M Buy
+31,315
New +$875K ﹤0.01% 2948
2016
Q3 		– Sell
-19,849
Closed -$215K – 3634
2016
Q2 		$215K Buy
+19,849
New +$270K ﹤0.01% 3166

David Shaw's AIMT Position: Q4 2020 in Review

David Shaw sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 15,530 shares — an estimated $535K sold.

David Shaw first reported a position in AIMT in Q2 2016 and held it in 5 quarters. The position peaked at $2.63M in Q2 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • David Shaw reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • David Shaw sold 15,530 Aimmune Therapeutics shares in Q4 2020, an estimated $535K.
  • David Shaw first reported a position in Aimmune Therapeutics in Q2 2016 and held it in 5 quarters.
  • David Shaw's Aimmune Therapeutics position peaked at $2.63M in Q2 2020.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on D.E. Shaw & Co's 13F filing for Q4 2020, filed 16 Feb 2021.